From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer&#39;s Disease.

Leqembi (lecanemab-irmb) - Biogen, Eisai

Kisunla (donanemab-azbt) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42742914

; Agnes Flöel; Anna Hofmann; Anna Hufnagel; Frank Jessen; Johannes Levin; Lutz Froelich; Oliver Peters; Robert Perneczky; Timo Grimmer

Sep 16, 2026